About AirXpanders
AirXpanders is a company based in Mountain View (United States) founded in 2006. AirXpanders has raised $36.15 million across 12 funding rounds from investors including GE Capital, Oxford Finance and Western Technology Investment. AirXpanders operates in a competitive market with competitors including Sientra, Establishment Labs, GC Aesthetics, BioAesthetics and Mpathy Medical Devices, among others.
- Headquarter Mountain View, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Axp Energy Limited
-
Annual Revenue
$608.02 K (USD)38.21as on Jun 30, 2024
-
Net Profit
-$3.53 M (USD)37.44as on Jun 30, 2024
-
EBITDA
-$1.15 M (USD)26.3as on Jun 30, 2024
-
Total Equity Funding
$36.15 M (USD)
in 12 rounds
-
Latest Funding Round
$3.4 M (USD), Post-IPO
Sep 11, 2018
-
Investors
GE Capital
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AirXpanders
AirXpanders is a publicly listed company on the ASX with ticker symbol AXP in Australia, operating in the Energy minerals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of AirXpanders
AirXpanders has successfully raised a total of $36.15M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.4 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $3.4M
-
First Round
First Round
(01 Mar 2008)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2018 | Amount | Post-IPO - AirXpanders | Valuation |
investors |
|
| Aug, 2017 | Amount | Debt – Conventional - AirXpanders | Valuation |
investors |
|
| Feb, 2017 | Amount | Post-IPO - AirXpanders | Valuation |
investors |
|
Investors in AirXpanders
AirXpanders has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include GE Capital, Oxford Finance and Western Technology Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Health-focused venture capital investments are made in US sectors.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AirXpanders
Financial Statements - AirXpanders
Airxpanders Comparisons
Competitors of AirXpanders
AirXpanders operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sientra, Establishment Labs, GC Aesthetics, BioAesthetics and Mpathy Medical Devices, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Products for plastic surgery and aesthetics are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Silicone-filled breast and body shaping implants are designed and manufactured.
|
|
| domain | founded_year | HQ Location |
Silicone breast implants are developed for reconstruction and aesthetic surgery.
|
|
| domain | founded_year | HQ Location |
Tissue-engineered nipple-areolar complexes are developed for post-mastectomy use.
|
|
| domain | founded_year | HQ Location |
Surgical meshes for treating women's urinary incontinence are developed.
|
Frequently Asked Questions about AirXpanders
AirXpanders was founded in 2006 and raised its 1st funding round 2 years after it was founded.
AirXpanders is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
AirXpanders is a funded company, having raised a total of $36.15M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $34.65M, raised on Mar 01, 2008.
Annual revenue of AirXpanders is $608.02K as on Jun 30, 2024.
AirXpanders was founded in 2006 and is based in Mountain View, United States. Medical devices for tissue expansion in post-mastectomy reconstructive surgery are developed, with a focus on breast reconstruction. The AeroForm expander is designed for patient control, allowing CO2 doses to be administered via a wireless device to gradually stretch skin tissue. This supports preparation for permanent implants in the reconstructive process.
AirXpanders's top competitors include Establishment Labs, GC Aesthetics and Sientra.
Yes, AirXpanders is publicly traded on ASX under the ticker symbol AXP.
AirXpanders has 7 investors. Key investors include GE Capital, Oxford Finance, Western Technology Investment, Vivo Capital, and GBS.
The ticker symbol of AirXpanders is AXP on ASX.